Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04OTY
|
||||
Former ID |
DIB001535
|
||||
Drug Name |
BFH-772
|
||||
Synonyms |
NVP-BFH-772
|
||||
Indication | Psoriasis [ICD9: 696; ICD10:L40] | Phase 2 | [1] | ||
Company |
Novartis AG
|
||||
Structure |
![]() |
Download2D MOL |
|||
Target and Pathway | |||||
Target(s) | VEGF receptor | Target Info | Agonist | [2] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health. | ||||
REF 2 | CA patent application no. 841416, Method of selecting therapeutic indications. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.